Author:
Mauskopf Josephine,Earnshaw Stephanie
Publisher
Springer International Publishing
Reference13 articles.
1. Asche CV, Clay E, Kharitonova E, Zah V, Ruby J, Aballea S. Budgetary impact of the utilization of buprenorphine/naloxone sublingual film and tablet for Medicaid in the United States. J Med Econ. 2015;18(8):600–11.
2. Bajaj PS, Veenstra DL, Goertz HP, Carlson JJ. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis. J Med Econ. 2014;17(8):538–46. doi:
10.3111/13696998.2014.912987
.
3. Caro JJ, Huybrechts KF, Xenakis JG, O’Brien JA, Rajagopalan K, Lee K. Budgetary impact of treating acute bipolar mania in hospitalized patients with quetiapine: an economic analysis of clinical trials. Curr Med Res Opin. 2006;22(11):2233–42.
4. Centers for Medicare and Medicaid Services. Physician fee schedule and acute inpatient prospective payment system.
http://www.cms.hhs.gov/PhysicianFeeSched/PFSFRN/list.asp#TopOfPage
and
http://www.cms.hhs.gov/Acutelnpatient
PPS/. Accessed 18 Oct 2006. Cited in: Danese et al. 2008.
5. Danese MD, Reyes C, Northridge K, Lubeck D, Lin CY, O’Connor P. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. Clin Ther. 2008;30(4):775–84.